BioTechnique sells the Madison parenteral facility to LSNE
BioTechnique sells 5501 Research Park Blvd Facility to LSNE, April 19, 2018 – relocates to 603 Science Drive, Madison, WI 53719
BioTechnique Completes IND
BioTechnique completes IND clinical trial material for oncology client, April 18, 2018
BioTechnique Completes ANDA
BioTechnique completes ANDA registration batches for Anderson Pharma, April 10. 2018.
BioTechnique Fills First Product
BioTechnique has officially filled its first product for a major charitable trust. Click below to read the full story on LinkedIn.
Pfizer's vetting process sorts the strategic CMOs from the casual flings
Outsourcing from a Small Pharma Perspective
Original source: Pharma Outsourcing
Author: Dawn Toronto, PhD
Does the slogan “bigger is better” hold true for outsourcing pharmaceutical activities? In previous years, the “one stop shop” Contract Manufacturing Organization (CMO) was all the rage and the benefits, apparently, were many: reduced costs, improved knowledge sharing, more efficient technology transfer, and shorter timelines.
BIOforward Announces Winners of 2014 Emerging Company Showcase
Original Source: Businesswire.com
Author: Brian Moeller
Five Wisconsin bioscience companies have been selected as the winners of BIOforward’s 2014 Emerging Company Showcase, sponsored by The Center for Technology Commercialization, Madison Gas and Electric (MGE), and First Business Bank.
California Biotech Firm to Hire 100-plus to Make Cancer Drugs
Original Source: Source
Author: Karen Rivedal
A California biotech consulting firm that pledged to create at least 103 local jobs by 2017 will get a $1 million low-interest loan from the state to help it buy an under-used pharmaceutical manufacturing facility in University Research Park where it plans to make cancer-fighting and other types of drugs for other companies.
Global Biotech Company Launches New Venture in Madison
PSC Investments Announces Acquisition of Manufacturing Facility
PSC Investments, a subsidiary of California based PSC Biotech Corporation, is proud to announce the acquisition of a high potency sterile injectable facility from the Morgridge Institute for Research (MIR), a private research institute affiliated with the University of Wisconsin-Madison.
The 37,000 square foot sterile injectable fill finish facility, located in Madison’s University Research Park was constructed in 2008 by Mentor Biologics, Inc. and later conveyed to MIR.
PSC Investments partnered with Steve Mixtacki, Chief Financial and Operating Officer of the Wisconsin Alumni Research Foundation (WARF), an affiliate of MIR, who said “…PSC has been a pleasure to work with, and we wish them much success at 5501 Research Park Boulevard”. Additionally, PSC Investments was very pleased with the outcome of the acquisition. “This was a great team effort from PSC Investments to help drive future growth potentials for PSC, and more importantly, help meet the high demand for cytotoxic and high potency fill-finish contract manufacturing services of sterile injectable products”, stated Raphi Hanessian, Managing Director of PSC Investments. The acquisition was financed with an SBA real estate loan from East West Bank in partnership with the CDC Small Business Finance team.
The recent acquisition of the pharmaceutical manufacturing facility will allow BioTechnique the opportunity to provide specialized filling services for cytotoxic, high potency, biologic, and other sterile injectable drugs. The injectable facility is state-of-the-art for filling and finishing high potency compounds and was designed to meet the highest safety levels for manufacturing personnel, as well as to minimize cross contamination, and be compliant with current Good Manufacturing Practices (cGMP) for sterile injectable manufacturing.
BioTechnique will be customer ready for sterile liquid and lyophilization fill-finish production in 2015.